Clinical Monograph #0428
Peer-Reviewed Medical Literature
ICD-10-CM: L71.9

Rosacea: Comprehensive Clinical Pathophysiology, Phenotypic Classification, Pharmacotherapy, and Evidence-Based Interventions

Lead Author: DermatologySense Clinical Content Working Group
Medically Reviewed by: Board-Certified Dermatologists (FAAD)
Pharmacology Reviewer: Clinical PharmD Specialist (Infectious & Cutaneous Pharmacotherapy)

Clinical Review Date: September 2026 | Annual Audit Cycle
Primary Consensus Standard: Global ROSCO (Rosacea Consensus) Panel
Level of Evidence: Grade A Systematic Reviews & Double-Blind RCTs

📋 Clinical Practice Takeaways (Executive Summary)

Modern Paradigm Shift: The National Rosacea Society (NRS) and the Global ROSCO panel have transitioned from rigid subtype categories to a patient-centric phenotypic classification. Diagnosis is confirmed by either fixed centrofacial erythema or phymatous changes.
Pathophysiologic Triad: Rosacea is fundamentally characterized by (1) dysregulated innate immune signaling (abnormal serine protease KLK5 cleaving cathelicidin into pro-inflammatory peptide LL-37), (2) cutaneous neurovascular hyperreactivity mediated by TRP ion channels (TRPV1, TRPA1), and (3) elevated density of the commensal pilosebaceous mite Demodex folliculorum and its endosymbionts.
Comedone Absence as Cardinal Differentiator: The clinical absence of open and closed comedones (blackheads/whiteheads) is the single most definitive criterion separating papulopustular rosacea from acne vulgaris.
Topical First-Line Hierarchy: Topical Ivermectin 1% cream displays superior clearance rates over Metronidazole 0.75% in active papulopustular lesions. Azelaic Acid 15% gel/foam provides dual anti-inflammatory and tyrosinase-inhibiting efficacy without microbial resistance pressure.
Subantimicrobial Systemic Strategy: When oral intervention is indicated, modified-release Doxycycline (40 mg daily) achieves non-antibiotic anti-inflammatory inhibition of matrix metalloproteinases (MMP-8, MMP-9) while preserving the human gut and cutaneous microbiome.

1. Cellular Pathophysiology: Molecular Mechanisms of Rosacea

Rosacea is an incurable, chronic inflammatory, neurovascular disorder affecting an estimated 5.46% of the global adult population, with highest prevalence observed in individuals of Northern European descent (Fitzpatrick phototypes I and II). Historically mischaracterized as an “acneiform eruption,” molecular breakthroughs over the past decade have dismantled this misconception. Rosacea is fundamentally driven by a complex interplay of innate immune system hyperreactivity, cutaneous neurovascular dysregulation, and microbial dysbiosis.

Figure 1: The Molecular Pathophysiology Cascade of Rosacea

EPIDERMAL CASCADES TLR2 Receptor Stimulation ↑ Kallikrein 5 (KLK5) (Serine Protease) Cleavage of hCAP-18 ↓ Abnormal LL-37 Peptides

IMMUNE & VASCULAR Mast Cell Degranulation Release of IL-8, TNF-α ↑ VEGF Angiogenesis ↑ MMP-2, MMP-9 Matrix Substance P / CGRP (Neurogenic Vasodilation)

PHENOTYPE • Persistent Erythema • Telangiectasias • Inflammatory Papules & Pustules • Tissue Hyperplasia • Stinging & Burning

Schematic adapted from Yamasaki & Gallo (Nature Medicine) and Two et al. (JAAD).

A. Innate Immune Hyperactivation: The KLK5 / LL-37 Pathway

At the cellular level, keratinocytes in rosacea patients express elevated baseline concentrations of Toll-Like Receptor 2 (TLR2). Stimulation of TLR2 by environmental triggers, ultraviolet radiation, or microbial byproducts triggers an abnormal transcription cascade that dramatically increases the epidermal serine protease known as kallikrein-related peptidase 5 (KLK5).

KLK5 is responsible for enzymatic cleavage of the precursor protein human cathelicidin (hCAP-18). In healthy skin, this yields normal antimicrobial fragments. In rosacea patients, however, overactive KLK5 processing generates distinct, truncated antimicrobial peptides designated LL-37. These anomalous LL-37 peptides demonstrate potent pro-inflammatory, angiogenic, and chemotactic properties:

They directly induce cutaneous mast cell degranulation, releasing histamine, leukotrienes, and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
They stimulate endothelial cells to secrete Vascular Endothelial Growth Factor (VEGF), stimulating pathologically dilated, hyperpermeable new capillary loops (telangiectasias).
They activate Matrix Metalloproteinases (specifically MMP-8 and MMP-9), which dismantle the dermal extracellular matrix, impairing structural capillary support and perpetuating tissue edema.

Expert Commentary — Immunodermatology Chair:
“The identification of the cathelicidin-KLK5 axis fundamentally rewrote our clinical approach. Rosacea is not an infection of the pore; it is an innate peptide-mediated autoimmune-inflammatory response wherein normal physiological defense proteins become destructive engines of cutaneous vascular damage.”

— Dr. Richard L. Gallo, MD, PhD, Distinguished Professor of Dermatology, UC San Diego School of Medicine

B. Neurovascular Dysregulation & Transient Receptor Potential (TRP) Ion Channels

Facial skin possesses an exceptionally dense network of sensory neurons and superficial vascular beds. Cutaneous sensory nerves in rosacea patients overexpress specific cation channels belonging to the Transient Receptor Potential (TRP) superfamily, particularly TRPV1 (vanilloid 1) and TRPA1 (ankyrin 1):

TRPV1: Activated by thermal heat (>43°C), spicy dietary constituents (capsaicin), ultraviolet light, and cellular acidification (low pH).
TRPA1: Stimulated by cold ambient air, volatile irritants, formaldehydes, and mustard oils (cinnamaldehyde).

When activated, these channels release vasoactive neuropeptides including Substance P, Calcitonin Gene-Related Peptide (CGRP), and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP). These neuropeptides trigger instantaneous arteriolar vasodilation, rapid capillary engorgement (visible flushing), increased vascular permeability, and cutaneous plasma extravasation, accompanied by severe subjective neuropathic pain described as deep burning and stinging.

C. The Microbiome Hypothesis: Demodex Mite Density & Endosymbionts

While microscopic Demodex folliculorum and Demodex brevis mites represent normal human follicular commensals, their cutaneous population density is statistically aberrant in rosacea. Quantitative microscopic surface biopsies confirm that patients presenting with papulopustular rosacea harbor up to 5.7 to 8 times higher densities of Demodex mites per square centimeter than age-matched controls (>5 mites/cm² being clinically diagnostic of demodicosis).

Demodex mites damage follicular epithelial lining through mechanical disruption via keratin digestion and enzymatic lipase secretion. When mites perish within the follicle, they release internal bacterial endosymbionts, predominantly Bacillus oleronius and Staphylococcus epidermidis strains. These bacterial antigens directly stimulate follicular TLR2 receptors and mononuclear cell proliferation, unleashing neutrophilic infiltration that translates clinically into acute inflammatory papules and sterile pustules.

2. The Modern Phenotypic Classification (Global ROSCO Consensus)

In 2002, the National Rosacea Society established a standardized subtype framework (Subtypes 1 through 4). While clinically convenient, this classification possessed significant therapeutic limitations because patients frequently exhibit overlapping features simultaneously.

In 2017–2019, the Global Rosacea Consensus (ROSCO) panel, composed of international dermatologists and ophthalmologists, overhauled diagnostic criteria to a phenotype-directed model. Under current clinical guidelines, therapy targets specific individual phenotypic signs rather than umbrella subtype categories.

Phenotype Classification	Clinical Presentation	Diagnostic Weight	Underlying Biological Mechanism
Fixed Centrofacial Erythema	Persistent, non-transient redness over convexities of the face (nose, medial cheeks, chin, forehead). Spares periocular skin.	DIAGNOSTIC (Alone confirms rosacea)	Dermal vascular ectasia, constant precapillary sphincter relaxation, basal vascular hyperpermeability.
Phymatous Changes	Tissue hypertrophy, patulous follicular orifices, lobulated irregular surface contour. Most commonly rhinophyma (nose).	DIAGNOSTIC (Alone confirms rosacea)	Chronic lymphedema, TGF-β upregulation, massive sebaceous gland hyperplasia, progressive interstitial dermal fibrosis.
Inflammatory Papules & Pustules	Dome-shaped erythematous papules and surmounting superficial sterile pustules. Completely devoid of comedones.	MAJOR CRITERION (Requires ≥2 major criteria)	Neutrophilic perivascular and perifollicular infiltrates, Demodex antigenic response, IL-8 & LL-37 cytokine surges.
Flushing (Transient Erythema)	Sudden, intense warm facial flushing, typically lasting >10 minutes. Frequently induced by heat, emotion, or alcohol.	MAJOR CRITERION	Autonomic neurogenic reflex, axon reflex release of Substance P and CGRP, acute vascular smooth muscle relaxation.
Telangiectasias	Visibly dilated, tortuous superficial cutaneous blood vessels, prominent along nasal ala and malar eminences.	MAJOR CRITERION	Permanent loss of elastic recoil in superficial dermal capillaries, chronic VEGF stimulation, vascular structural remodeling.
Ocular Manifestations	Lid margin telangiectasias, meibomian gland dysfunction, conjunctivitis, foreign body sensation, recurrent chalazia.	MAJOR CRITERION	Periorbital Demodex migration, cathelicidin expression in tears, meibomian lipid stagnation leading to evaporative tear film collapse.
Secondary Signs: Stinging, Edema, Dryness	Cutaneous burning upon application of bland products; central facial non-pitting edema; scaly dry appearance despite normal sebum.	SECONDARY CRITERION (Supportive evidence)	Elevated Transepidermal Water Loss (TEWL), defective stratum corneum barrier, intraepidermal naked C-fiber hypersensitivity.

3. Differential Diagnosis: Distinguishing Rosacea from Mimickers

Accurate diagnosis is paramount. Misdiagnosing rosacea as acne vulgaris or contact dermatitis often prompts prescription of harsh comedolytic topicals or fluorinated topical corticosteroids, which can induce catastrophic disease exacerbation (“steroid-induced rosacea”).

Dermatological Condition	Comedones Present?	Primary Anatomical Distribution	Distinguishing Clinical Hallmarks	Diagnostic Testing / Confirmation
Papulopustular Rosacea	ABSOLUTELY NO	Centrofacial convexities: nose, medial cheeks, chin, glabella.	Background erythema, visible telangiectasias, acute flushing episodes, neuropathic stinging.	Standardized skin surface biopsy (SSSB) for Demodex count.
Acne Vulgaris	ALWAYS YES	Face (including jawline/temples), chest, upper back, shoulders.	Open comedones (blackheads), closed comedones (whiteheads), deep inflammatory cysts, post-acne scarring.	Clinical evaluation; hyperseborrhea, follicular plug extraction.
Seborrheic Dermatitis	No	Nasolabial folds, eyebrow hair, scalp, external ear canals.	Greasy, yellowish scales over erythematous plaques; prominent pruritus (itching) rather than burning.	KOH preparation demonstrates Malassezia yeast; therapeutic trial of topical antifungals.
Perioral Dermatitis	No	Perioral, perinasal, and periocular zones with clear vermilion rim.	Micro-papules and micro-vesicles; distinct 1–2mm spared zone immediately around the lip vermilion border.	History of inhaled, oral, or fluorinated topical corticosteroid usage.
Systemic Lupus (SLE)	No	Malar “butterfly” distribution spanning across the nasal bridge.	Completely spares the nasolabial folds; lacks pustules; associated with systemic arthralgias and fatigue.	Serology: Antinuclear antibodies (ANA), anti-dsDNA, anti-Smith; punch biopsy with direct immunofluorescence.

4. Evidence-Based Topical Pharmacotherapy Compendium

The therapeutic objective in managing rosacea is targeting the distinct pathological drivers: dampening innate immune hyperactivation, neutralizing Demodex mite burdens, and chemically regulating the vascular tone.

Active Pharmaceutical Ingredient (API)	Mechanism of Action (MOA)	Approved Concentrations & Vehicles	Dosing Protocol & Onset	Clinical Trial Efficacy (Cochrane/FDA)
Topical Ivermectin (Soolantra)	Binds glutamate-gated chloride channels in Demodex invertebrates causing neuro-paralysis; downregulates IL-1β, TNF-α, and COX-2.	1% Cream (Cetyl/Stearyl alcohol hydrophilic base).	Once daily at bedtime. Initial response at week 2; maximal efficacy at week 12.	Phase III head-to-head trial (ATTRACT) proved Ivermectin 1% significantly superior to Metronidazole 0.75% in lesion reduction (84.9% vs. 70.7%).
Azelaic Acid (AzA) (Finacea)	Inhibits KLK5 serine protease transcription; scavenges reactive oxygen species (superoxide radicals); suppresses neutrophil activation.	15% Gel, 15% Hydrophilic Foam, 20% Cream.	Twice daily (AM & PM). Response observed in 4–6 weeks.	Maintains >75% inflammatory lesion reduction in multicenter trials. Non-teratogenic (FDA Pregnancy Category B).
Metronidazole (MetroGel, Noritate)	Inhibits neutrophilic free-radical generation; suppresses cellular DNA synthesis; reduces local microvascular permeability.	0.75% Gel, 0.75% Cream, 0.75% Lotion, 1.0% Cream.	0.75% twice daily or 1.0% once daily. Response in 6–8 weeks.	Historic standard-of-care. Excellent tolerability, but exhibits lower lesion clearance metrics compared to Ivermectin.
Brimonidine Tartrate (Mirvaso)	Selective alpha-2 adrenergic receptor agonist; induces direct vasoconstriction of superficial facial dermal arterioles.	0.33% Aqueous Gel.	Once daily in the morning (pea-sized amount). Rapid onset (30 minutes); peak vasoconstriction at 3–4 hours; duration 10–12 hours.	Dramatically reduces persistent erythema; DOES NOT clear inflammatory bumps. Caution: Up to 15% experience paradoxical rebound erythema upon clearance.
Oxymetazoline HCl (Rhofade)	Selective alpha-1A adrenergic agonist; produces sustained smooth muscle contraction in subcutaneous microvasculature.	1% Cream.	Once daily in the morning. Smooth onset, 12-hour sustained duration.	Statistically lower rates of rebound vasodilation (<3%) compared to Brimonidine tartrate gel due to differing receptor specificity profiles.

⚠️ Pharmacotherapy Warning: Topical Corticosteroid Trap

Never prescribe or apply medium-to-high potency topical corticosteroids to facial rosacea. While steroids induce temporary vasoconstriction, they downregulate local innate immunity, provoke massive Demodex proliferation, destroy dermal collagen scaffolding, and trigger catastrophic steroid-induced rosacea characterized by cutaneous atrophy, severe rebound flare-ups, and refractory telangiectasias.

5. Oral Therapeutics & Systemic Protocols

Systemic pharmacotherapy is indicated for moderate-to-severe papulopustular presentations, cases failing first-line topical combination therapy, ocular rosacea involvement, and early-stage active phymatous disease.

A. Subantimicrobial-Dose Doxycycline: The Non-Antibiotic Revolution

Standard bactericidal antibiotic doses of doxycycline (100–200 mg daily) were historically utilized under the flawed assumption that rosacea was caused by cutaneous bacterial infection. Today, clinical practice centers on anti-inflammatory subantimicrobial dosing (SDD):

Regimen: 40 mg modified-release capsule once daily (formulated as 30 mg immediate-release and 10 mg delayed-release beads; trade name Oracea).
Pharmacodynamics: This unique formulation maintains steady-state plasma concentrations between 0.3 and 0.6 μg/mL. This concentration sits strictly below the minimum inhibitory concentration (MIC) required to exert antibiotic selective pressure on human microflora.
Mechanism: SDD potently inhibits matrix metalloproteinases (MMP-8, MMP-9, MMP-13), stops the degradation of dermal procollagen fibers, inhibits protein kinase C pathways, and reduces neutrophil chemotaxis without inducing vaginal candidiasis or bacterial resistance.

B. Oral Isotretinoin (Low-Dose Protocols)

For severe, disfiguring, or refractory papulopustular rosacea, and for halting early active-stage rhinophyma before permanent fibrotic scarring settles, oral 13-cis-retinoic acid (Isotretinoin) is the definitive modality.

Dosing Paradigm: In contrast to the high cumulative doses prescribed for cystic acne (120–150 mg/kg), rosacea responds to micro-dose or low-dose off-label regimens: 10 to 20 mg daily (or 0.25–0.3 mg/kg/day) for 4 to 6 months, subsequently tapered to 10 mg twice weekly as maintenance.
Clinical Mechanism: Downregulates sebaceous gland volume by up to 90%, starves Demodex populations dependent on sebum lipids, suppresses TLR2 expression on keratinocytes, and halts pro-fibrotic cytokine signaling.
Monitoring: Requires mandatory iPLEDGE program adherence, strict contraception (teratogenicity), and regular monitoring of lipid panels and hepatic transaminases.

C. Autonomic Vascular Modulators (Beta-Blockers & Clonidine)

For neurogenic rosacea dominated by excruciating emotional or physiological flushing that resists topical alpha-agonists, systemically active autonomic agents provide targeted symptom control:

Carvedilol: Administered at 6.25 mg to 12.5 mg twice daily; suppresses both cutaneous beta-receptor-mediated vasodilation and alpha-mediated vascular capacitance.
Propranolol: 20 mg to 40 mg taken 60 minutes prior to documented flushing triggers.
Clonidine: 0.05 mg twice daily; blunts central sympathetic outflow, mitigating vasodilation spikes.

6. Energy-Based & Procedural Dermatology: Laser Modalities

Pharmacological topicals and oral pills are clinically incapable of eliminating permanently dilated structural telangiectasias or organized fibrous tissue hyperplasia. Energy-based vascular platforms represent the gold standard for vascular remodeling.

Laser / Light Platform	Wavelength / Spectrum	Target Chromophore	Clinical Indication	Clinical Clearance & Recovery Profile
Pulsed Dye Laser (PDL) (Vbeam)	595 nm	Oxyhemoglobin (542nm & 577nm peaks)	Superficial telangiectasias, confluent background erythema, post-inflammatory redness.	Selective photothermolysis destroys intravascular RBCs, collapsing vessel walls without epidermal necrosis. Typically requires 2–4 sessions spaced 4 weeks apart. Mild purpura/edema for 48–72 hours.
Intense Pulsed Light (IPL) (BBL / Stellar M22)	515–1200 nm (Broadband with cut-off filters)	Oxyhemoglobin & Melanin	Diffuse facial flushing, mixed photoaging with concurrent solar lentigines.	Non-coherent pulsed light. Excellent for generalized background redness; less targeted for discrete large-caliber vessel eradication than PDL. Zero downtime.
Long-Pulsed Nd:YAG	1064 nm	Deoxyhemoglobin & Deep vascular plexus	Deeper, thicker caliber, violaceous or bluish telangiectasias (>0.5 mm diameter).	High dermal penetration depth. High safety in darker phototypes (Fitzpatrick IV–V) due to lower melanin absorption competing at 1064 nm.
Ablative CO2 / Erbium Laser	10,600 nm (CO2) / 2940 nm (Er:YAG)	Intracellular Tissue Water	Moderate-to-severe Phymatous Rosacea (Rhinophyma).	Surgical contouring and debulking of hyperplastic sebaceous tissue. Re-epithelialization occurs via adnexal follicular reservoirs over 10–14 days.

7. Ocular Rosacea: Manifestations & Ophthalmic Management

Ocular rosacea is frequently underdiagnosed by clinicians, occurring in up to 58% to 72% of all rosacea patients. Crucially, in 20% of patients, ocular symptoms precede cutaneous manifestations, often leading to months of misdirected treatment for allergic conjunctivitis.

Key Clinical Presentations

Blepharitis: Erythematous eyelid margins with prominent collarettes and crusting along the cilia.
Meibomian Gland Dysfunction (MGD): Inspissated, turbid meibum secretion leading to rapid tear evaporation.
Recurrent Hordeola & Chalazia: Sterile granulomatous blockages of meibomian orifices.
Sight-Threatening Complications: Corneal neovascularization, marginal keratitis, corneal ulceration, and eventual perforation.

Evidence-Based Ocular Protocol

Lid Margin Hygiene: Warm compresses (10 minutes bid) followed by gentle cleansing using 0.01% Hypochlorous acid (HOCl) eyelid sprays.
Topical Cyclosporine 0.05% Drops (Restasis): Twice daily to suppress T-cell-mediated ocular inflammation and increase natural tear production.
Oral Doxycycline 40mg (Modified Release): Uniquely effective at reducing bacterial lipase production and liquefying meibomian lipids.
Omega-3 Fatty Acid Supplementation: 2,000 mg EPA/DHA daily to modulate the meibum lipidome.

8. The Neurogenic Trigger Cascade & Clinical Dietetics

Lifestyle and environmental triggers do not cause the underlying genetic predisposition to rosacea; rather, they act as primary physiological stimuli that directly depolarize sensitized neuroreceptors (TRPV1 and TRPA1) and activate TLR2 innate immune cascades.

The 6 Evidence-Verified Trigger Classes (NRS Patient Cohort Data)

Solar Radiation (81% of patients): Ultraviolet B (UVB) generates high levels of reactive oxygen species (ROS), induces acute cellular cathelicidin cleavage, and upregulates VEGF production within 30 minutes of exposure.
Emotional Stress & Anxiety (79%): Sympathetic outflow triggers direct release of peripheral norepinephrine, acetylcholine, and PACAP, causing uninhibited arteriolar dilation.
Thermal Heat & Steam (75%): Hot baths, saunas, weather transitions (>25°C), and heated beverages directly trigger the thermal sensory threshold of TRPV1 ion channels.
Ethanol & Alcoholic Beverages (52%): Alcohol metabolizes into acetaldehyde, a potent vasoactive compound. Red wine contains high concentrations of free histamines and tyramine, which exacerbate mast cell degranulation.
Capsaicin & Cinnamaldehyde in Spices (45%): Hot peppers (capsaicin) and foods containing cinnamaldehyde (tomatoes, citrus fruits, cinnamon) bind directly to TRP ion channels on lingual and cutaneous nerve endings.
Aerobic Physical Exertion (56%): Systemic core thermoregulation drives physiological facial cutaneous perfusion to shed excess heat.

9. Physiological Barrier Repair: Skincare Regimen Architecture

The stratum corneum in rosacea patients demonstrates persistent impairment characterized by abnormally high Transepidermal Water Loss (TEWL) and reduced epidermal concentrations of ceramides and essential fatty acids. This compromised barrier allows topical substances to penetrate directly onto naked sensory nerve terminals, causing stinging and chronic low-grade neurogenic inflammation.

Clinical Morning (AM) Regimen Framework

Cleanse: Rinse face with lukewarm water or apply a soap-free, non-foaming synthetic detergent cleanser (syndet, pH 5.0–5.5). Pat dry with a clean microfiber cloth; never rub.
Targeted Topical: Apply prescribed Azelaic Acid 15% Gel or Brimonidine/Oxymetazoline (if managing persistent baseline erythema). Allow 5 minutes for epidermal absorption.
Physiological Barrier Repair Cream: Formulations containing identical 3:1:1 physiological lipid ratios (Ceramides NP/AP/EOP, Cholesterol, and Free Fatty Acids) combined with soothing agents (Madecassoside, Colloidal Oat, or Niacinamide 2–4%).
Photoprotection: Broad-spectrum SPF 50+ utilizing 100% Mineral Physical Shields (Zinc Oxide 12–20% ± Titanium Dioxide). Mineral filters reflect UV photons without generating thermal kinetic heat in the epidermis. Tinted formulas incorporating iron oxides provide vital protection against high-energy visible (HEV) blue light.

Clinical Evening (PM) Regimen Framework

Cleanse: Gentle lipid-replenishing micellar water or a gentle emulsifying cleansing lotion to dissolve mineral SPF and atmospheric particulate pollutants without stripping intercellular lipids.
Targeted Medication: Apply a thin pea-sized layer of Topical Ivermectin 1% Cream (Soolantra) across the entire face (cheeks, forehead, chin, nose) to suppress Demodex populations during their nocturnal emergence.
Occlusive Barrier Sealant: High-density ceramide-rich barrier balm (containing Dimethicone 1–2% or Squalane) to establish a protective barrier and arrest overnight TEWL.

10. Peer-Reviewed Academic References & Clinical Citations

The clinical guidelines and therapeutic protocols compiled in this monograph are synthesized strictly from peer-reviewed dermatology literature, meta-analyses, and double-blind randomized clinical trials (Level 1 Evidence).

Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology. 2018;78(1):148-155. doi:10.1016/j.jaad.2017.08.029
Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSCO panel 2019. British Journal of Dermatology. 2020;182(5):1269-1276. doi:10.1111/bjd.18420
van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database of Systematic Reviews. 2015;(4):CD003262. doi:10.1002/14651858.CD003262.pub5
Yamasaki K, Di Nardo A, Barlan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine. 2007;13(8):975-980. doi:10.1038/nm1616
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part I. Introduction, categorization, histology, pathogenesis, and risk factors. Journal of the American Academy of Dermatology. 2015;72(5):749-758. doi:10.1016/j.jaad.2014.08.028
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: Part II. Topical and systemic therapies in the precision treatment of rosacea. Journal of the American Academy of Dermatology. 2015;72(5):761-770. doi:10.1016/j.jaad.2014.08.027
Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial (ATTRACT). British Journal of Dermatology. 2015;172(4):1103-1110. doi:10.1111/bjd.13408
Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. Journal of the American Academy of Dermatology. 2013;69(6 Suppl 1):S15-S26. doi:10.1016/j.jaad.2013.04.045
Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized trials of 40-mg anti-inflammatory-dose doxycycline capsules in the treatment of rosacea. Journal of the American Academy of Dermatology. 2007;56(5):791-802. doi:10.1016/j.jaad.2006.11.026
Forton FM, De Maertelaer V. Papulopustular rosacea and rosacea-like demodicosis: two phenotypes of the same disease? Journal of the European Academy of Dermatology and Venereology. 2018;32(6):1011-1016. doi:10.1111/jdv.14884
Neuhaus IM, Zane LT, Webster GF. Comparative efficacy of pulsed dye laser and intense pulsed light in the management of erythematotelangiectatic rosacea. Dermatologic Surgery. 2009;35(6):920-928. doi:10.1111/j.1524-4725.2009.01156.x
American Academy of Dermatology (AAD). Rosacea Clinical Guidelines & Diagnostic Criteria. Available at: https://www.aad.org/public/diseases/rosacea. Accessed September 2026.